Increased serum levels of lipopolysaccharide and anti-flagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome.
Dlugosz A, Nowak P, D’Amato M, Kermani GM, Nystrom J, Abdurahman S, Lindberg G.
Neurogastroenterol Motil. 2015; 27: 1747-54. FI: 3.310 (Q2).
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S Lee J, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A Juyal R, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard T, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK, The International Multiple Sclerosis Genetics Consortium, The International IBD Genetics Consortium, Barrett JC, Alizadeh BZ, Parkes M, Thelma BK, Daly MJ, Kubo M, Anderson CA, Weersma RK.
Nat Genet. 2015; 47: 979-86. FI: 31.616 (Q1).
RAD21 and APOB molecular defects in chronic instestinal pseudo-obstruction.
Bonora E, Bianco F, Cordeddu L, Bamshad M, Francescatto L, Dowless D, Stanghellini V, Cogliandro RF, Lindberg G, Mungans Z, Cefle K, Ozcelik T, Palanduz S, Ozturk S, Gedikbasis A, Gori A, Pippucci T, Graziano C, Volta U, Caio G, Barbara G, D’Amato M, Seri M, Katsanis N, Rome G, De Giorgio R.
Gastroenterology. 2015; 148: 771-82. FI: 18.187 (Q1).
Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multi-national case-control cohorts.
Ek WE, Reznichenko A, Ripke S, Niesler B, Zucchelli M, Rivera NV, Schmidt PT, Pedersen NL, Magnusson P, Talley NJ, Holliday EG, Houghton L, Gazouli M, Karamanolis G, Rappold G, Burwinkel B, Surowy H, Rafter J, Assadi G, Li L, Papadaki E, Gambaccini D, Marchi S, Colucci R, Blandizzi C, Barbaro R, Karling P, Walter S, Ohlsson B, Tornblom H, Bresso F, Andreasson A, Dlugosz A, Simren M, Agreus L, Lindberg G, Boeckxstaens G, Bellini M, Stanghellini V, Barbara G, Daly MJ, Camilleri M, Wouters MM, D'Amato M.
Gut. 2015; 64: 1774-82. FI: 14.921 (Q1).
High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.
Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, Ripke S, Gusareva ES, Annese V, Hauser SL, Oksenberg JR, Thomsen I, Leslie S, International Inflammatory Bowel Disease Genetics Consortium, Australia and New Zealand IBDGC, Belgium IBD Genetics Consortium, Italian Group for IBD Genetic Consortium, NIDDK Inflammatory Bowel Disease Genetics Consortium, United Kingdom IBDGC, Wellcome Trust Case Control Consortium, Quebec IBD Genetics Consortium, Daly MJ, Van Steen K, Duerr RH, Barrett JC, McGovern DP, Schumm LP, Traherne JA, Carrington MN, Kosmoliaptsis V, Karlsen TH, Franke A, Rioux JD.
Nat Genet. 2015; 47: 172-9. FI: 31.616 (Q1).
Severe, gastrointestinal dysmotility developed after treatment with gonadotropin-releasing hormone analogs.
Cordeddu L, Bergvall M, Sand E, Roth B, Papadaki E, Li L, D’Amato M, Ohlsson B.
Scand J Immunol. 2015; 50:291-299. FI: 2.199 (Q3).
